UBS Group’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $73.8M | Buy |
983,378
+456,761
| +87% | +$29.3M | 0.01% | 1369 |
|
|
2026
Q1 | $29.7M | Sell |
526,617
-13,060
| -2% | -$851K | ﹤0.01% | 2186 |
|
|
2025
Q4 | $43.3M | Sell |
539,677
-912,894
| -63% | -$61.3M | 0.01% | 1764 |
|
|
2025
Q3 | $70.8M | Buy |
1,452,571
+582,782
| +67% | +$36.1M | 0.01% | 1309 |
|
|
2025
Q2 | $64.9M | Buy |
869,789
+453,692
| +109% | +$30M | 0.01% | 1286 |
|
|
2025
Q1 | $26.4M | Buy |
416,097
+223,585
| +116% | +$15.2M | ﹤0.01% | 2085 |
|
|
2024
Q4 | $15M | Buy |
192,512
+168,466
| +701% | +$13.5M | ﹤0.01% | 2643 |
|
|
2024
Q3 | $1.93M | Buy |
24,046
+5,240
| +28% | +$423K | ﹤0.01% | 4026 |
|
|
2024
Q2 | $1.56M | Sell |
18,806
-39,308
| -68% | -$3.46M | ﹤0.01% | 4012 |
|
|
2024
Q1 | $4.96M | Sell |
58,114
-13,973
| -19% | -$1.1M | ﹤0.01% | 2984 |
|
|
2023
Q4 | $6.16M | Buy |
72,087
+27,618
| +62% | +$2.39M | ﹤0.01% | 2551 |
|
|
2023
Q3 | $3.98M | Sell |
44,469
-25,399
| -36% | -$2.27M | ﹤0.01% | 2795 |
|
|
2023
Q2 | $5.95M | Buy |
69,868
+11,056
| +19% | +$935K | ﹤0.01% | 2413 |
|
|
2023
Q1 | $4.87M | Buy |
58,812
+15,563
| +36% | +$1.26M | ﹤0.01% | 2547 |
|
|
2022
Q4 | $3.4M | Buy |
43,249
+37,274
| +624% | +$3M | ﹤0.01% | 2852 |
|
|
2022
Q3 | $442K | Buy |
5,975
+919
| +18% | +$66K | ﹤0.01% | 4448 |
|
|
2022
Q2 | $329K | Sell |
5,056
-14,800
| -75% | -$876K | ﹤0.01% | 4574 |
|
|
2022
Q1 | $1.26M | Sell |
19,856
-13,583
| -41% | -$739K | ﹤0.01% | 3867 |
|
|
2021
Q4 | $1.77M | Buy |
33,439
+30,020
| +878% | +$1.83M | ﹤0.01% | 3834 |
|
|
2021
Q3 | $241K | Sell |
3,419
-275
| -7% | -$17.4K | ﹤0.01% | 5185 |
|
|
2021
Q2 | $246K | Sell |
3,694
-14,433
| -80% | -$1.02M | ﹤0.01% | 5209 |
|
|
2021
Q1 | $2.01M | Sell |
18,127
-5,276
| -23% | -$653K | ﹤0.01% | 3565 |
|
|
2020
Q4 | $2.78M | Sell |
23,403
-13,209
| -36% | -$1.42M | ﹤0.01% | 3069 |
|
|
2020
Q3 | $3.19M | Buy |
36,612
+30,890
| +540% | +$2.7M | ﹤0.01% | 2621 |
|
|
2020
Q2 | $512K | Sell |
5,722
-5,792
| -50% | -$585K | ﹤0.01% | 4124 |
|
|
2020
Q1 | $1.15M | Sell |
11,514
-104,784
| -90% | -$11.4M | ﹤0.01% | 3241 |
|
|
2019
Q4 | $13.4M | Buy |
116,298
+60,904
| +110% | +$7.37M | ﹤0.01% | 1690 |
|
|
2019
Q3 | $6.99M | Buy |
55,394
+26,586
| +92% | +$3.37M | ﹤0.01% | 2077 |
|
|
2019
Q2 | $3.47M | Sell |
28,808
-10,210
| -26% | -$1M | ﹤0.01% | 2636 |
|
|
2019
Q1 | $3.41M | Sell |
39,018
-20,231
| -34% | -$1.84M | ﹤0.01% | 2517 |
|
|
2018
Q4 | $5.93M | Sell |
59,249
-2,484
| -4% | -$261K | ﹤0.01% | 2004 |
|
|
2018
Q3 | $7.07M | Buy |
61,733
+26,961
| +78% | +$2.79M | ﹤0.01% | 2057 |
|
|
2018
Q2 | $3.12M | Buy |
34,772
+20,376
| +142% | +$1.72M | ﹤0.01% | 2761 |
|
|
2018
Q1 | $1.05M | Buy |
14,396
+2,185
| +18% | +$150K | ﹤0.01% | 3668 |
|
|
2017
Q4 | $709K | Sell |
12,211
-4,085
| -25% | -$215K | ﹤0.01% | 4038 |
|
|
2017
Q3 | $731K | Buy |
16,296
+4,814
| +42% | +$200K | ﹤0.01% | 3942 |
|
|
2017
Q2 | $453K | Sell |
11,482
-1,230
| -10% | -$50.5K | ﹤0.01% | 4178 |
|
|
2017
Q1 | $516K | Sell |
12,712
-6,340
| -33% | -$248K | ﹤0.01% | 4009 |
|
|
2016
Q4 | $766K | Buy |
19,052
+7,246
| +61% | +$273K | ﹤0.01% | 3781 |
|
|
2016
Q3 | $427K | Sell |
11,806
-1,829
| -13% | -$62.8K | ﹤0.01% | 4024 |
|
|
2016
Q2 | $396K | Buy |
13,635
+3,534
| +35% | +$107K | ﹤0.01% | 4067 |
|
|
2016
Q1 | $353K | Buy |
10,101
+3,287
| +48% | +$106K | ﹤0.01% | 4051 |
|
|
2015
Q4 | $220K | Sell |
6,814
-3,401
| -33% | -$110K | ﹤0.01% | 4590 |
|
|
2015
Q3 | $330K | Buy |
10,215
+1,895
| +23% | +$71.3K | ﹤0.01% | 4227 |
|
|
2015
Q2 | $344K | Buy |
8,320
+2,992
| +56% | +$126K | ﹤0.01% | 4411 |
|
|
2015
Q1 | $239K | Buy |
5,328
+1,811
| +51% | +$75.7K | ﹤0.01% | 4734 |
|
|
2014
Q4 | $132K | Buy |
+3,517
| New | +$129K | ﹤0.01% | 5425 |
|
Other funds holding HAE
AI
UBS Group's HAE Position: Q2 2026 in Review
UBS Group increased its Haemonetics (HAE) stake by 87% in Q2 2026, buying an estimated $29.3M and bringing the position to 983,378 shares worth $73.8M. The position accounts for 0.01% of the portfolio, ranked #1369.
UBS Group first reported a position in HAE in Q4 2014 and has held it in 47 quarters since. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.
- UBS Group held 983,378 shares of Haemonetics worth $73.8M as of Q2 2026.
- UBS Group bought 456,761 Haemonetics shares in Q2 2026, an estimated $29.3M.
- Haemonetics made up 0.01% of UBS Group's portfolio in Q2 2026, its #1369 holding.
- UBS Group first reported a position in Haemonetics in Q4 2014 and has held it in 47 quarters since.
- 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.